⌕
Kiniksa Pharmaceuticals International · KNSA · Nasdaq
Tenet 55 · Mixed
Compare
$95.11+0.93%At closeTenet 55 · Mixed
$95.11+0.88 (+0.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kiniksa Pharmaceuticals International (KNSA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~104.8%/yr (FY21→FY25), net margin 8.7%, and free cash flow (~$136.4M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+15.2%) and Capex step-up ($1.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲60.1%
677.6
FY21→FY25CAGR +104.8%/yr
Net income ($M)—
59.0
one-off year: see footnoteCAGR −31.5%/yr
Free cash flow ($M)▲440.1%
136.4
capex stepped upCAGR —
Diluted EPS—
0.75
FY22→FY25CAGR −33.9%/yr
What the receipts whisper · what a headline number hides
Share count
+15.2%

68.6mn → 79.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$1.6M

▲265% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)677.6Revenue−307.2COGS370.3Gross profit−96.9R&D−196.3SG&A77.2Op income−18.2Tax & other59.0Net income

9¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 74.2% → 54.7%. Net margin 8.7% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
945,963.0677,564.0423,239.0270,259.0220,180.038,544.0▲60.1%+104.8%
Cost of revenue
432,576.0307,218.0189,221.089,931.046,966.09,935.0▲62.4%+135.8%
Gross profit
513,387.0370,346.0234,018.0180,328.0173,214.028,609.0▲58.3%+89.7%
Research & development
135,769.096,853.0111,623.076,097.065,490.099,297.0▼13.2%−0.6%
Selling, general & admin
247,153.0196,272.0168,011.0129,427.097,951.085,948.0▲16.8%+22.9%
Total operating expenses
382,922.0293,125.0279,634.0205,524.0163,441.0185,245.0▲4.8%+12.2%
Operating incomefeeds ROC rank
130,465.077,221.0−45,616.0−25,196.09,773.0−156,636.0—+99.2% (22→25)
Other income, net
15,687.011,647.09,464.08,544.01,253.097.0——
Pretax income
146,152.088,868.0−36,152.0−16,652.011,026.0−156,539.0—+100.5% (22→25)
Income tax
36,584.029,863.07,041.0−30,736.0−172,337.01,385.0▲324.1%+115.5%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
109,568.059,005.0−43,193.014,084.0183,363.0−157,924.0—−31.5% (22→25)
Per share
Diluted EPSbuyback-sensitive
1.310.75−0.600.202.60−2.30—−33.9% (22→25)
Diluted shares (mn)
84.9278.9871.4271.9270.4268.58▲10.6%+3.6%
Margins
Gross margin35th pct in Healthcare
54.3%54.7%55.3%66.7%78.7%74.2%▼0.6pp−19.6pp
Operating margin
13.8%11.4%−10.8%−9.3%4.4%−406.4%▲22.2pp+417.8pp
Net margin72nd pct in Healthcare
11.6%8.7%−10.2%5.2%83.3%−409.7%▲18.9pp+418.4pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −1563% vs a −1% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was 185% vs a −1% norm for this window, likely a one-time item; see the filing.
FY17 – FY20 · 4 more years
Unlock the full history →
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Kiniksa Pharmaceuticals International's revenue last fiscal year?

Kiniksa Pharmaceuticals International reported revenue of $677.6M in fiscal 2025, up 60.1% from fiscal 2024.

What was Kiniksa Pharmaceuticals International's net income?

Kiniksa Pharmaceuticals International reported net income of $59.0M in fiscal 2025, a net margin of 8.7%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.